For fumarate, its succination of GAPDH in immune cells was suggested to underlie the immunomodulatory activity of dimethylfumarate, an FDA-approved drug to treat multiple sclerosis, an auto-immune inflammatory disease (Kornberg et al. 2018), (Cheng et al. 2023). Here, GAPDH is linked to multiple sclerosis.